Department of Otolaryngology, Stanford University, Stanford, CA, USA.
Klinik fur Hals-, Nasen-, Ohren- Krankheiten, Hals-und Gesichtschirurgie, Kantonsspital Aarau, Switzerland.
Rhinology. 2020 Jun 1;58(3):194-199. doi: 10.4193/Rhin19.248.
The frequencies of systemic antibiotics and oral corticosteroids taken for chronic rhinosinusitis (CRS) indicate poor CRS disease control. We sought to determine the validity and responsiveness of these metrics as reflections of CRS disease burden.
One hundred and eighty-seven patients undergoing medical management for CRS were recruited. Participants were assessed at two time points: enrollment and a follow-up appointment three to nine months later. At each time point, CRS related antibiotic and oral corticosteroid usage in the previous three months was measured, while general and disease-specific quality of life (QOL) was measured using the visual analog scale of the 5-dimension EuroQol questionnaire (EQ-5D VAS) and the 22-item Sinonasal Outcome Test (SNOT-22), respectively.
The frequency of CRS-related antibiotics and oral corticosteroids use was cross-sectionally correlated with EQ-5D VAS and SNOT-22 at the corresponding time points. For participants reporting usage of these medications at enrollment, there was a decrease of 1 course per 3 months for both CRS-related antibiotics and oral corticosteroids. Change in CRS-related antibiotics from enrollment to follow-up was correlated with change in both EQ-5D and SNOT-22 over the same timeframe. The change in CRSrelated oral corticosteroids was correlated with change in both EQ-5D VAS and SNOT-22). These correlations were stronger in the subset of patients who had a change in these metrics over the study period.
The frequencies of CRS-related antibiotic use and oral corticosteroid use are valid and responsive measures of CRS disease burden.
慢性鼻-鼻窦炎(CRS)患者全身使用抗生素和口服皮质类固醇的频率表明其 CRS 疾病控制不佳。我们旨在确定这些指标作为 CRS 疾病负担的反映的有效性和反应性。
招募了 187 名正在接受 CRS 药物治疗的患者。参与者在两个时间点接受评估:入组时和随访预约,时间为 3 至 9 个月后。在每个时间点,测量过去三个月中与 CRS 相关的抗生素和口服皮质类固醇的使用情况,同时使用 5 维欧洲健康调查问卷的视觉模拟量表(EQ-5D VAS)和 22 项鼻-鼻窦结局测试(SNOT-22)分别测量一般和疾病特异性生活质量(QOL)。
CRS 相关抗生素和口服皮质类固醇使用的频率与相应时间点的 EQ-5D VAS 和 SNOT-22 呈横断面相关。对于在入组时报告使用这些药物的参与者,CRS 相关抗生素和口服皮质类固醇的使用量每 3 个月减少 1 个疗程。从入组到随访时 CRS 相关抗生素的变化与同一时间段内 EQ-5D 和 SNOT-22 的变化相关。CRS 相关口服皮质类固醇的变化与 EQ-5D VAS 和 SNOT-22 的变化相关。在研究期间这些指标发生变化的患者亚组中,这些相关性更强。
CRS 相关抗生素使用和口服皮质类固醇使用的频率是 CRS 疾病负担的有效和敏感的衡量标准。